国内常用慢性乙肝核苷类抗病毒药物疗效差异性比较

The difference between clinical efficacy of nucleoside antiviral drugs of chronic hepatitis B in Chinese literature

目的 比较常用核苷类抗病毒药物疗效差异.方法 检索近3年核苷（酸）类似物拉米夫定、阿德福韦酯、恩替卡韦的临床药效报道,并进行分析.结果 不同报道中使用拉米夫定、阿德福韦酯、恩替卡韦治疗52（48）周的HBV-DNA阴转率分别为43.00%～85.00%、38.50%～94.00%和74.00%～87.50% HBeAg血清转换率（或阴转率）为18.00%～35.50%、9.80%～43.60%和0～38.90% ALT复常率为69.00%～94.70%、64.10%～100.0%和87.50%～91.00%.结论 拉米夫定、阿德福韦酯、恩替卡韦治疗慢性乙型肝炎疗效差异很大,需将药物与患者实际情况结合进行治疗.

Objective Identify the difference in the use of Nucleoside analogues. Methods Search nearly 3-year clinical efficacy reports about nucleoside （acid） analogues like Lamivudine and Adefovir dipivoxil, Entecavir,and analyze the inner of the difference. Resaula In different reports, the effects of Nucleoside analogues bring a significant difference, including the HBV-DNA negative rate, Serum conversion rate of HBeAg, and Normalization rate of ALT. Conclusion When dealing with the Chronic Hepatitis B, Lamivudine and Adefovir dipivoxil, Entecavir have great different in effect, Doctor should take the actual situation in patients with the drug combination treatment.